Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...
Clinical Trials Arena on MSN12d
Novo Nordisk’s stock drops despite CagriSema hitting goal of Phase III trialThe Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in ...
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Novo Nordisk (NVO, Financial) shares fell 8% on Monday morning following disappointing Phase 3 trial results for its weight ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...
Shares of Novo Nordisk slipped in Monday morning trading ... in people with overweight or obesity and type 2 diabetes," said Martin Holst Lange, executive vice president for development at Novo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback